Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Stereotactic Body Radiotherapy Followed by Sintilimab Plus Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer With Contralateral Mediastinal (N3) Lymph Node Metastasis: A Prospective Phase II Clinical Trial

NCT07309952 is registered in ClinicalTrials.gov with Yang Hong as lead sponsor.

NCT NCT07309952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07309952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Stereotactic Body Radiotherapy Followed by Sintilimab Plus Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer With Contralateral Mediastinal (N3) Lymph Node Metastasis: A Prospective Phase II Clinical Trial
Lead sponsor
Yang Hong
Phase
Phase 2
Overall status
Recruiting
Start date
December 31, 2025
Completion date
October 31, 2032
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iiic non-small cell lung cancer